Faculty
Oncology Division
Alphabetical list (active faculty):   
Douglas R. Adkins

Douglas R. Adkins, MD

Professor

Department of Medicine

Oncology Division

Medical Oncology

Clinical Interests

  • Head and neck cancer
  • Thyroid cancer

Contact

  • 314-747-8475 (office)
  • 314-362-7086 (fax)
  • Division of Oncology
    Mail Stop 8056-0029-11
    Washington University
    660 South Euclid Avenue
    St. Louis, MO 63110
  • 11th Floor Mid-Campus Center (office)

Research

Areas of Clinical Research Interest

Head and Neck Cancer

  • 1. CDK4/6 inhibitors
  • 2. Immunotherapy
  • 3. VEGFR inhibitors
  • 4. EZH2 inhibitors
  • 5. PARP inhibitors
  • 6. Nanoparticle albumin-bound paclitaxel
  • 7. EGFR, Her-3 and MTOR inhibitors

Thyroid Cancer

  • 1. Targeted agents in the treatment of medullary, differentiated and anaplastic thyroid cancers

Current Research Projects

Head and Neck Cancer

  • 1. A Prospective Phase I and II Trial of Ramucirumab + Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
  • 2. Los Tres PasosTrial: Step One - Neoadjuvant Palbociclib Monotherapy, Step Two - Concurrent Chemoradiation Therapy, and Step Three - Adjuvant Palbociclib Monotherapy in Patients with p16INK4a Negative, HPV-Unrelated Head and Neck Squamous Cell Carcinoma
  • 3. Pembrolizumab (MK-3475) in locoregionally advanced, surgically resectable HPV-Unrelated head and neck squamous cell carcinoma
  • 4. Tazemetostat and Pembrolizumab in Patients with Pembrolizumab- or Nivolumab-Resistant, Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma: A Phase 1-2 Trial
  • 5. Olaparib in Combination with Pembrolizumab and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma: A Single-Arm, Phase 2 Trial
  • 6. Nab-Paclitaxel + Nivolumab for HNSCC that Progressed on a PD-1 Inhibitor: A Single-Arm, Phase 2 Trial
  • 7. Participation in cooperative group (RTOG, ECOG, SWOG, P2C), pharmaceutical and multi-institutional investigator initiated clinical trials in SCCHN

Thyroid Cancer

  • 1. Participation in cooperative group (P2C, Alliance) and pharmaceutical clinical trials in thyroid cancer: 17-AAG (P2C), Zactima, Sorafenib, XL184/Cabozantinib (Exelixis), CS-7017 (Daiichi Sankyo Pharma), Pazopanib (P2C), Cediranib/Lenalidomide (P2C), Efatutazone (Alliance), LOXO-292/Selpercatinib (Lilly), BLU-667/Pralsetinib (Blue)